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COMMENTS AND
RESPONSES
International Expert
Committee Report on
the Role of the A1C
Assay in the
Diagnosis of
Diabetes
Response to the International
Expert Committee
M
embers of the International Ex-
pert Committee have recom-
mended that diabetes should be
diagnosedifA1Cis6.5%,withoutneed
tomeasuretheplasmaglucoseconcentra-
tion (1). We are concerned that practical
limitations will lead to false positives and
negatives with this approach.
A given A1C instrument may identify
some but not other abnormal hemoglo-
bins (http://www.ngsp.org/prog/index2.
html). How, therefore, can we be sure
whether a hemoglobinopathy is causing
(or preventing) diagnosis? Before diagno-
sis, should we not also exclude iron deﬁ-
ciency anemia, which may increase A1C
by 1–1.5%, as well as hemolytic anemia
and renal failure or chronic infections,
which also lower A1C (2)? The Interna-
tional Expert Committee breezes over the
effect of aging (0.4% higher in 70-year-
old subjects than in 40-year-old subjects,
apparently, despite the same glucose tol-
erance) and ethnicity (0.5% higher in
Afro-Caribbeans than Europids) because
their “etiology and signiﬁcance are un-
clear.” Before this matter is settled, surely
potential overdiagnosis of the elderly and
non-Europids is inappropriate? These is-
sues,andthepossiblelistoftestsrequired
in addition to the simple A1C, still make
the idea of fasting overnight for a glucose
test an attractive option.
How well does A1C compare with
glucose in predicting microvascular risk?
The International Expert Committee
mentions three studies (on Egyptian pop-
ulation and Pima Indians and the Na-
tional Health and Nutrition Examination
Survey) that demonstrate risk of retinop-
athy increasing with rising fasting plasma
glucose, 2-h glucose, and A1C levels in a
similar fashion; this is expected within a
population no matter how poorly one of
the tests predicts risk compared with an-
other. In all three studies, however, re-
ceiver operating characteristic analysis
shows fasting and/or 2-h glucose mea-
surement to be superior to A1C. One
study cited to justify the 6.5% A1C cutoff
evenfoundthatrandomglucoseprovided
“similar results” (3). It is, of course, not
possible to comment on the report’s un-
published personal communication.
What about the recommended cutoff
of 6.5%? The National Health and Nutri-
tion Examination Survey data show over
half of subjects with fasting plasma glu-
cose 126 mg/dl have an A1C 6.5%
(4). If fasting glucose is measured in any
of this majority, will they or will they not
havediabetes?Inindividualswhoneedto
haveglucosemeasuredbecausetheirA1C
is known to be unreliable, is it discrimi-
natory for them to have a two to three
times greater chance of diagnosis than
subjectswithouthemoglobinopathy,ane-
mia, renal failure, etc.?
On the basis of current evidence,
there is far less risk of an individual sub-
ject being completely misdiagnosed with
fasting and 2-h glucose than with A1C.
There is a clear case for further discussion
and evidence before decisions are made
bytheAmericanDiabetesAssociation,the
European Association for the Study of Di-
abetes, the International Diabetes Feder-
ation,andtheWorldHealthOrganization
on the merits of an A1C-only approach
and the speciﬁc cutoff point for diagnosis
of diabetes to identify subjects at in-
creased microvascular risk.
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